RESEARCH ARTICLE


Impending Flop for Brand Antiretrovirals in the Emerging Markets?



Dionisio Daniele 1 , &, Messeri Daniela 2
2 “Access to Drugs: International Policies” - CLIA (Italian Network for International Fight against AIDS), Italian Soci-ety for Infectious and Tropical Diseases (SIMIT), Division of Infectious Diseases, Pistoia Hospital, Pistoia, Italy
2 Division of Infectious Diseases, Pistoia Hospital, Pistoia, Italy


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 1724
Abstract HTML Views: 837
PDF Downloads: 253
Total Views/Downloads: 2814
Unique Statistics:

Full-Text HTML Views: 913
Abstract HTML Views: 458
PDF Downloads: 161
Total Views/Downloads: 1532



© Dionisio and Messeri; Licensee Bentham Open

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.

& at the Infectious Disease Division, Pistoia Hospital, Piazza Giovanni XXIII 1, Pistoia, Italy; Tel: 0039-0573-352324; Fax: 0039-0573-352309; E-maid.dionisio@usl3.toscana.it


Abstract

Forecasts from Country choices, South-South partnerships and Clinton Foundation-UNITAID coalition show that present policies for brand ARVs are at the risk of flop in emerging South markets such as India, China, Thailand and Brazil.

The dynamics explored in this article highlight the risks the originator companies are running in the emerging markets, along with their interest in direct agreements with the generic industry for the manufacturing and marketing of ARVs.

Resulting information here would suggest the brand enterprises:

  • To look for fast registration of their ARVs by regulatory authorities in all countries enlisted for differential pricing.
  • To secure all formulations differentiated prices.
  • To align with the Clinton-UNITAID prices for the corresponding generics.
  • To pursue flexible negotiations with the generic companies to secure both counterparts long-term advantages.